The efficacy and safety of Niaoduqing granules in the treatment of diabetic kidney disease: a systematic review and meta-analysis
Background: Diabetic nephropathy (DN) is the main cause of chronic kidney disease (CKD) and end-stage renal failure (ESRF), and the control of disease progression and adverse events during treatment needs to be improved.Objective: This study aimed to systematically evaluate the clinical efficacy and...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1180751/full |
| _version_ | 1797786706191056896 |
|---|---|
| author | Chaoqun Song Zhiyue Zhu Le Liu Shilin Liu Yuandong Li Yang Xiao Chunwei Wu Zheng Nan Zheng Nan |
| author_facet | Chaoqun Song Zhiyue Zhu Le Liu Shilin Liu Yuandong Li Yang Xiao Chunwei Wu Zheng Nan Zheng Nan |
| author_sort | Chaoqun Song |
| collection | DOAJ |
| description | Background: Diabetic nephropathy (DN) is the main cause of chronic kidney disease (CKD) and end-stage renal failure (ESRF), and the control of disease progression and adverse events during treatment needs to be improved.Objective: This study aimed to systematically evaluate the clinical efficacy and safety of Niaoduqing granules (NDQG) in the treatment of diabetic kidney disease (DKD).Method: Randomized controlled trials (RCTs) of NDQG for DKD from Chinese and English databases up to 31 August 2022 were included. The quality of the literature was assessed using the risk of bias tool of the Cochrane Handbook. At a 95% confidence interval (CI), relative risk (RR) and Cohen’s d were used for the categorical and continuous variables, respectively, and Stata 16.0 software was used for statistical analysis. A funnel plot and Egger’s tests were used to assess publication bias.Result: A total of 4,006 patients were included in 52 RCTs, including 1,987 cases in the control group and 2,019 cases in the treatment group. Compared with conventional treatment (CT), combined NDQG therapy is more effective in improving clinical efficiency [RR = 1.23, 95% confidence interval (1.17, 1.29), p < 0.001, I2 = 53.17%], kidney function (urinary albumin excretion rate [SMD = −0.90, 95% CI (−1.14, −0.66), p < 0.001, I2 = 78.19%], 24hUTP levels [SMD = −0.81, 95% CI (−1.08, −0.55), p < 0.001, I2 = 87.08%], blood urea nitrogen [SMD = −0.54, 95% CI (−0.69, −0.39), p < 0.01, I2 = 77.01%], SCr [SMD = −0.68, 95% CI (−0.90, −0.45), p < 0.001, I2 = 89.97%], CCr [SMD = 0.76, 95% CI (0.10,1.42), p = 0.02, I2 = 95.97%], and Cys-C [SMD = −1.32, 95% CI (−2.25, −0.40), p = 0.01, I2 = 93.44%]), the level of glucose metabolism (fasting blood glucose [SMD = −0.18, 95% CI (−0.38, 0.03), p = 0.10, I2 = 71.18%] and HbA1c [SMD = −0.42, 95% CI (−0.86, −0.02), p = 0.06, I2 = 81.64%]), the level of lipid metabolism (total cholesterol [SMD = −0.70, 95% CI (−1.01, −0.39), p < 0.001, I2 = 86.74%] and triglyceride [SMD = −0.61, 95% CI (−0.87,−0.36), p < 0.001, I2 = 80.64%]), inflammatory factors (Hs-CRP [SMD = −1.00, 95% CI (−1.54, −0.46), p < 0.001, I2 = 86.81%], IL-18 [SMD = −1.25, 95% CI (−1.58, −0.92), p < 0.001, I2 = 0], and TNF-α [SMD = −1.28, 95% CI (−1.64, −0.91), p < 0.001, I2 = 75.73%]), and indicators of oxidative stress (malondialdehyde [SMD = −0.88, 95% CI (−1.22, −0.54), p < 0.001, I2 = 66.01%] and advanced oxidation protein products [SMD = −0.92, 95% CI (−1.85, 0.00), p < 0.001, I2 = 90.68%]). In terms of improving uric acid [SMD = −1.59, 95% CI (−3.45, 0.27), p = 0.09, I2 = 94.67%], 2hPG [SMD = −0.04, 95% CI (−0.61, 0.53), p = 0.89, I2 = 84.33%], HDL-C [SMD = 0.71, 95% CI (0.02, 1.40), p = 0.04, I2 = 87.43%], Hb [SMD = 0.11, 95% CI (−0.10, 0.32), p = 0.32, I2 = 0.00]), and superoxide dismutase [SMD = 1.32, 95% CI (0.44, 2.20), p < 0.001, I2 = 93.48%], the effect is not obvious. Adjuvant treatment with NDQG did not increase the incidence of adverse reactions in the control group [SMD = 0.98, 95% CI (0.71, 1.34), p = 0.89, I2 = 1.59%]. Obvious publication bias was detected by funnel plot and Egger’s test.Conclusion: Our meta-analysis showed that adjuvant treatment with NDQG has more advantages than conventional treatment alone in the DKD treatment, which could improve clinical efficiency, kidney function, the level of glucose metabolism, the level of lipid metabolism, inflammatory factors, and oxidative stress indicators. At the same time, it also showed that NDQG are relatively safe. However, more high-quality studies are needed to provide more reliable evidence for clinical use.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022373726, identifier CRD42022373726. |
| first_indexed | 2024-03-13T01:11:45Z |
| format | Article |
| id | doaj.art-6e6d19d79fe3449598bc38bafc8274a1 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-13T01:11:45Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-6e6d19d79fe3449598bc38bafc8274a12023-07-05T17:52:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-07-011410.3389/fphar.2023.11807511180751The efficacy and safety of Niaoduqing granules in the treatment of diabetic kidney disease: a systematic review and meta-analysisChaoqun Song0Zhiyue Zhu1Le Liu2Shilin Liu3Yuandong Li4Yang Xiao5Chunwei Wu6Zheng Nan7Zheng Nan8Changchun University of Chinese Medicine, Changchun, ChinaChangchun University of Chinese Medicine, Changchun, ChinaChangchun University of Chinese Medicine, Changchun, ChinaChangchun University of Chinese Medicine, Changchun, ChinaChangchun University of Chinese Medicine, Changchun, ChinaChangchun University of Chinese Medicine, Changchun, ChinaChangchun University of Chinese Medicine, Changchun, ChinaChangchun University of Chinese Medicine, Changchun, ChinaThe Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, ChinaBackground: Diabetic nephropathy (DN) is the main cause of chronic kidney disease (CKD) and end-stage renal failure (ESRF), and the control of disease progression and adverse events during treatment needs to be improved.Objective: This study aimed to systematically evaluate the clinical efficacy and safety of Niaoduqing granules (NDQG) in the treatment of diabetic kidney disease (DKD).Method: Randomized controlled trials (RCTs) of NDQG for DKD from Chinese and English databases up to 31 August 2022 were included. The quality of the literature was assessed using the risk of bias tool of the Cochrane Handbook. At a 95% confidence interval (CI), relative risk (RR) and Cohen’s d were used for the categorical and continuous variables, respectively, and Stata 16.0 software was used for statistical analysis. A funnel plot and Egger’s tests were used to assess publication bias.Result: A total of 4,006 patients were included in 52 RCTs, including 1,987 cases in the control group and 2,019 cases in the treatment group. Compared with conventional treatment (CT), combined NDQG therapy is more effective in improving clinical efficiency [RR = 1.23, 95% confidence interval (1.17, 1.29), p < 0.001, I2 = 53.17%], kidney function (urinary albumin excretion rate [SMD = −0.90, 95% CI (−1.14, −0.66), p < 0.001, I2 = 78.19%], 24hUTP levels [SMD = −0.81, 95% CI (−1.08, −0.55), p < 0.001, I2 = 87.08%], blood urea nitrogen [SMD = −0.54, 95% CI (−0.69, −0.39), p < 0.01, I2 = 77.01%], SCr [SMD = −0.68, 95% CI (−0.90, −0.45), p < 0.001, I2 = 89.97%], CCr [SMD = 0.76, 95% CI (0.10,1.42), p = 0.02, I2 = 95.97%], and Cys-C [SMD = −1.32, 95% CI (−2.25, −0.40), p = 0.01, I2 = 93.44%]), the level of glucose metabolism (fasting blood glucose [SMD = −0.18, 95% CI (−0.38, 0.03), p = 0.10, I2 = 71.18%] and HbA1c [SMD = −0.42, 95% CI (−0.86, −0.02), p = 0.06, I2 = 81.64%]), the level of lipid metabolism (total cholesterol [SMD = −0.70, 95% CI (−1.01, −0.39), p < 0.001, I2 = 86.74%] and triglyceride [SMD = −0.61, 95% CI (−0.87,−0.36), p < 0.001, I2 = 80.64%]), inflammatory factors (Hs-CRP [SMD = −1.00, 95% CI (−1.54, −0.46), p < 0.001, I2 = 86.81%], IL-18 [SMD = −1.25, 95% CI (−1.58, −0.92), p < 0.001, I2 = 0], and TNF-α [SMD = −1.28, 95% CI (−1.64, −0.91), p < 0.001, I2 = 75.73%]), and indicators of oxidative stress (malondialdehyde [SMD = −0.88, 95% CI (−1.22, −0.54), p < 0.001, I2 = 66.01%] and advanced oxidation protein products [SMD = −0.92, 95% CI (−1.85, 0.00), p < 0.001, I2 = 90.68%]). In terms of improving uric acid [SMD = −1.59, 95% CI (−3.45, 0.27), p = 0.09, I2 = 94.67%], 2hPG [SMD = −0.04, 95% CI (−0.61, 0.53), p = 0.89, I2 = 84.33%], HDL-C [SMD = 0.71, 95% CI (0.02, 1.40), p = 0.04, I2 = 87.43%], Hb [SMD = 0.11, 95% CI (−0.10, 0.32), p = 0.32, I2 = 0.00]), and superoxide dismutase [SMD = 1.32, 95% CI (0.44, 2.20), p < 0.001, I2 = 93.48%], the effect is not obvious. Adjuvant treatment with NDQG did not increase the incidence of adverse reactions in the control group [SMD = 0.98, 95% CI (0.71, 1.34), p = 0.89, I2 = 1.59%]. Obvious publication bias was detected by funnel plot and Egger’s test.Conclusion: Our meta-analysis showed that adjuvant treatment with NDQG has more advantages than conventional treatment alone in the DKD treatment, which could improve clinical efficiency, kidney function, the level of glucose metabolism, the level of lipid metabolism, inflammatory factors, and oxidative stress indicators. At the same time, it also showed that NDQG are relatively safe. However, more high-quality studies are needed to provide more reliable evidence for clinical use.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022373726, identifier CRD42022373726.https://www.frontiersin.org/articles/10.3389/fphar.2023.1180751/fullNiaoduqing granulesdiabetic kidney diseasetraditional Chinese medicinesystematic reviewsmeta-analysis |
| spellingShingle | Chaoqun Song Zhiyue Zhu Le Liu Shilin Liu Yuandong Li Yang Xiao Chunwei Wu Zheng Nan Zheng Nan The efficacy and safety of Niaoduqing granules in the treatment of diabetic kidney disease: a systematic review and meta-analysis Frontiers in Pharmacology Niaoduqing granules diabetic kidney disease traditional Chinese medicine systematic reviews meta-analysis |
| title | The efficacy and safety of Niaoduqing granules in the treatment of diabetic kidney disease: a systematic review and meta-analysis |
| title_full | The efficacy and safety of Niaoduqing granules in the treatment of diabetic kidney disease: a systematic review and meta-analysis |
| title_fullStr | The efficacy and safety of Niaoduqing granules in the treatment of diabetic kidney disease: a systematic review and meta-analysis |
| title_full_unstemmed | The efficacy and safety of Niaoduqing granules in the treatment of diabetic kidney disease: a systematic review and meta-analysis |
| title_short | The efficacy and safety of Niaoduqing granules in the treatment of diabetic kidney disease: a systematic review and meta-analysis |
| title_sort | efficacy and safety of niaoduqing granules in the treatment of diabetic kidney disease a systematic review and meta analysis |
| topic | Niaoduqing granules diabetic kidney disease traditional Chinese medicine systematic reviews meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1180751/full |
| work_keys_str_mv | AT chaoqunsong theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT zhiyuezhu theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT leliu theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT shilinliu theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT yuandongli theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT yangxiao theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT chunweiwu theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT zhengnan theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT zhengnan theefficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT chaoqunsong efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT zhiyuezhu efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT leliu efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT shilinliu efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT yuandongli efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT yangxiao efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT chunweiwu efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT zhengnan efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis AT zhengnan efficacyandsafetyofniaoduqinggranulesinthetreatmentofdiabetickidneydiseaseasystematicreviewandmetaanalysis |